

**P&T Motion History
Targeted Immune Modulators (TIMs)**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>baricitinib guselkumab risankizumab tildrakizumab upadacitinib abatacept adalimumab anakinra apremilast brodalumab certolizumab pegol etanercept golimumab infliximab ixekizumab natalizumab rituximab sarilumab secukinumab tocilizumab tofacitinib ustekinumab vedolizumab</p>	<p>After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved indications, I move that: baricitinib, guselkumab, risankizumab, tildrakizumab, upadacitinib, abatacept, adalimumab, anakinra, apremilast, brodalumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, sarilumab, secukinumab, tocilizumab, tofacitinib, ustekinumab, vedolizumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis) and must include a self-administered agent if indicated.</p> <p>These medications cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Park 2nd: Storhaug</p>	<p>June 17, 2020</p>	<p>NA</p>	<p>No</p>	<p>Passed unanimous</p>